GET DAILY SIGNALSViemed Healthcare (VMD) Prepares for Q3 2026 Earnings Report
Key Takeaways
- Wall Street expects Viemed Healthcare to report earnings of $0.12 per share on revenue of roughly $80.78 million for the third quarter of 2026.
- The consensus figures imply earnings-per-share (EPS) growth of about 33% and revenue growth of about 12% versus the same quarter a year earlier.
- Viemed has missed consensus EPS in two consecutive quarters, most recently reporting $0.07 against a $0.12 estimate in the second quarter of 2026.
- Management has raised the low end of its full-year 2026 revenue guidance while trimming its adjusted EBITDA outlook, a signal that margins remain under pressure.
- Analysts currently hold a cautious "Hold" consensus rating, with price targets generally clustering around $12.50 to $14.00.
- For deeper coverage, you can review the company's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- To complement your own research, explore Trending AI Robots for data-driven trade ideas and market signals.
Earnings Context and Its Significance
Viemed Healthcare is a U.S.-based provider of in-home medical equipment and clinical services for patients with chronic respiratory and other complex conditions, including ventilation, oxygen therapy, and sleep-apnea care. Its third-quarter 2026 report matters because the company has struggled to convert strong revenue growth into bottom-line results. While top-line momentum has remained robust, a shift toward lower-margin services and product lines has compressed profitability, causing the stock to underperform after recent releases. Investors will be watching closely to see whether management's cost discipline and newer initiatives, such as maternal-health and sleep-resupply offerings, can stabilize margins and restore confidence in the earnings trajectory. I also checked this using Tickeron’s AI Screener to compare the stock against peers in the sector.
Earnings Expectations for Q3 2026
For the third quarter of fiscal 2026, which ended September 30, 2026, the consensus estimate calls for $0.12 in diluted EPS on $80.78 million in revenue. That compares with $0.09 per share on $71.91 million in revenue reported in the same period a year earlier, implying expected year-over-year growth of roughly 33% on earnings and 12% on revenue.
The bar has proven difficult in recent quarters. Viemed posted $0.07 per share in the second quarter of 2026, missing the $0.12 consensus by a wide margin even as revenue of $78.10 million slightly exceeded expectations. The company has beaten consensus EPS in only 2 of its last 8 quarters, making this report a key test of whether improved execution can translate into more reliable earnings delivery.
On guidance, management recently raised the low end of its full-year 2026 revenue outlook to $314 million–$320 million while narrowing adjusted EBITDA to $64 million–$68 million, down from the prior $65 million–$69 million range. Investors will focus on whether that reduced profitability expectation proves conservative or signals further margin erosion. From what I see in the numbers, this adjustment highlights ongoing pressures on the bottom line.
Market Reaction and Investor Sentiment
Sentiment heading into the third-quarter 2026 report remains cautious. Viemed shares have traded near the $9.70–$9.80 range in recent sessions, well below the 52-week high of $12.61, reflecting investor frustration with consecutive EPS misses. The most recent report triggered a sharp selloff as the market focused on margin compression rather than record revenue. With a consensus rating of "Hold" and limited analyst conviction, the stock enters this print with modest expectations. Key risk factors include continued business-mix shift toward lower-margin offerings, rising operating expenses tied to sales, technology, and capacity investments, and competitive pressures in the respiratory care market. A third straight earnings shortfall would likely renew pressure on the shares, while an in-line or better result could begin rebuilding credibility.
Forward Outlook and Key Factors to Monitor
Beyond the headline numbers, investors should watch several themes that will shape Viemed's path through the rest of 2026 and into 2027.
First is margin trajectory. The company's shift toward lower-margin services, combined with spending on technology and capacity, has weighed on adjusted EBITDA. Management has signaled that margins should stabilize rather than expand aggressively, so any evidence of improvement or further slippage will be closely scrutinized.
Second is guidance credibility. After raising the lower end of the revenue range but trimming the EBITDA outlook, Viemed needs to demonstrate that its growth investments are beginning to pay off in productivity and operating leverage, particularly in the second half of the year.
Third is diversification progress. The maternal-health and sleep-resupply initiatives are expected to be among the fastest-growing product lines, and commentary on payer-network expansion and cross-trained sales efforts will offer insight into the pace of adoption.
Finally, investors should monitor patient-count metrics, including active ventilator patients and PAP (positive airway pressure) therapy volumes, which reached record levels in recent quarters and serve as leading indicators of recurring revenue. Balanced execution across these factors will be essential for Viemed to move past its recent earnings misses. I’m watching this closely as the company works through these operational shifts.
Exploring Tickeron’s AI Tools in My Research
In my own analysis of names like Viemed, I often turn to Tickeron’s AI Screener to quickly scan for comparable setups across healthcare and filter by technical patterns or fundamentals. It helps surface ideas efficiently when building or refining a watchlist. The tool integrates well with daily signals and pattern recognition features that complement traditional research without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
VMD in -5.13% downward trend, falling for three consecutive days on November 02, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where VMD declined for three days, in 179 of 258 cases, the price declined further within the following month. The odds of a continued downward trend are 69%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for VMD moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 20 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VMD as a result. In 58 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.
The Moving Average Convergence Divergence Histogram (MACD) for VMD turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 58 similar instances when the indicator turned negative. In 40 of the 58 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
The 50-day moving average for VMD moved below the 200-day moving average on October 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
VMD broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
VMD moved above its 50-day moving average on October 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VMD crossed bullishly above the 50-day moving average on October 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +3.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where VMD advanced for three days, in 230 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 181 of 236 cases where VMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. VMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.674) is normal, around the industry mean (4.170). P/E Ratio (27.324) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (1.910) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (1.202) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the provision of home healthcare solutions
Industry MedicalNursingServices
Advertisement